+

WO2006024953A3 - Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues - Google Patents

Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues Download PDF

Info

Publication number
WO2006024953A3
WO2006024953A3 PCT/IB2005/002939 IB2005002939W WO2006024953A3 WO 2006024953 A3 WO2006024953 A3 WO 2006024953A3 IB 2005002939 W IB2005002939 W IB 2005002939W WO 2006024953 A3 WO2006024953 A3 WO 2006024953A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth hormone
human growth
preparation
methods
polyethylene glycol
Prior art date
Application number
PCT/IB2005/002939
Other languages
English (en)
Other versions
WO2006024953A2 (fr
Inventor
Rory F Finn
Ned R Siegel
Original Assignee
Pharmacia & Upjohn Co Llc
Rory F Finn
Ned R Siegel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006024953(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0515118-0A priority Critical patent/BRPI0515118A/pt
Priority to CA002577999A priority patent/CA2577999A1/fr
Priority to AP2007003919A priority patent/AP2007003919A0/xx
Priority to AU2005278903A priority patent/AU2005278903A1/en
Priority to EP05784225A priority patent/EP1789092A2/fr
Application filed by Pharmacia & Upjohn Co Llc, Rory F Finn, Ned R Siegel filed Critical Pharmacia & Upjohn Co Llc
Priority to JP2007529040A priority patent/JP2008511610A/ja
Priority to EA200700380A priority patent/EA200700380A1/ru
Priority to MX2007002441A priority patent/MX2007002441A/es
Publication of WO2006024953A2 publication Critical patent/WO2006024953A2/fr
Publication of WO2006024953A3 publication Critical patent/WO2006024953A3/fr
Priority to IL181085A priority patent/IL181085A0/en
Priority to TNP2007000078A priority patent/TNSN07078A1/fr
Priority to NO20071322A priority patent/NO20071322L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne la pégylation d'hormone de croissance humaine (hGH) au moyen d'un glycérol de PEG ramifié. La présente invention concerne aussi des processus de pégylation de hGH. Cette invention concerne aussi des compositions pharmaceutiques comprenant cette hormone de croissance humaine pegylatée. Un autre mode de réalisation de l'invention concerne l'utilisation de cette hormone de croissance humaine pegylatée destinée au traitement de troubles de la croissance et du développement.
PCT/IB2005/002939 2004-08-31 2005-08-25 Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues WO2006024953A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2007002441A MX2007002441A (es) 2004-08-31 2005-08-25 Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos.
EA200700380A EA200700380A1 (ru) 2004-08-31 2005-08-25 Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения
AP2007003919A AP2007003919A0 (en) 2004-08-31 2005-08-25 Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof
AU2005278903A AU2005278903A1 (en) 2004-08-31 2005-08-25 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
EP05784225A EP1789092A2 (fr) 2004-08-31 2005-08-25 Conjugués de l'hormone de croissance humaine avec du polyéthylèneglycol ramifié à l'aide de glycérol, procédé de sa préparation, et méthode de son utilisation.
BRPI0515118-0A BRPI0515118A (pt) 2004-08-31 2005-08-25 conjugados de hormÈnio do crescimento humano com polietileno glicol
JP2007529040A JP2008511610A (ja) 2004-08-31 2005-08-25 グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法
CA002577999A CA2577999A1 (fr) 2004-08-31 2005-08-25 Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues
IL181085A IL181085A0 (en) 2004-08-31 2007-01-31 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
TNP2007000078A TNSN07078A1 (fr) 2004-08-31 2007-02-27 Conjugues d'hormone de croissance humaine avec un polyethyleneglycol ramifie avec du glycerol, procede pour leur preparation et methodes pour leur utilisation
NO20071322A NO20071322L (no) 2004-08-31 2007-03-09 Humane veksthormonkonjugater av glyserolforgrenet polyetylenglycol, fremgangsmate for dens fremstilling og fremgangsmate for anvendelse derav

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31
US60/605,945 2004-08-31

Publications (2)

Publication Number Publication Date
WO2006024953A2 WO2006024953A2 (fr) 2006-03-09
WO2006024953A3 true WO2006024953A3 (fr) 2007-01-18

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002939 WO2006024953A2 (fr) 2004-08-31 2005-08-25 Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues

Country Status (24)

Country Link
EP (1) EP1789092A2 (fr)
JP (1) JP2008511610A (fr)
KR (1) KR20070042567A (fr)
CN (1) CN101010105A (fr)
AP (1) AP2007003919A0 (fr)
AR (1) AR050851A1 (fr)
AU (1) AU2005278903A1 (fr)
BR (1) BRPI0515118A (fr)
CA (1) CA2577999A1 (fr)
CR (1) CR8942A (fr)
EA (1) EA200700380A1 (fr)
EC (1) ECSP077281A (fr)
GT (1) GT200500235A (fr)
IL (1) IL181085A0 (fr)
MA (1) MA28908B1 (fr)
MX (1) MX2007002441A (fr)
NL (1) NL1029828C2 (fr)
NO (1) NO20071322L (fr)
PE (1) PE20060654A1 (fr)
TN (1) TNSN07078A1 (fr)
TW (1) TW200621291A (fr)
UY (1) UY29088A1 (fr)
WO (1) WO2006024953A2 (fr)
ZA (1) ZA200701802B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ502375A (en) 1997-07-14 2001-11-30 Bolder Biotechnology Inc The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
EP1144613B2 (fr) 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Techniques permettant de produire des proteines contenant des residus cysteine libres
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (fr) * 2006-03-13 2007-09-19 Siegfried Ltd. Conjugues de proteines et de dipolymeres et leurs procedes de preparation
CN101448525A (zh) * 2006-05-12 2009-06-03 东亚制药株式会社 聚乙二醇-干扰素α缀合物
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
KR101079993B1 (ko) 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
NZ590358A (en) * 2008-07-23 2012-04-27 Hanmi Holdings Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
JP5639585B2 (ja) 2008-07-31 2014-12-10 ファーマエッセンティア コーポレイション ペプチド−ポリマー共役体
EP2340271B1 (fr) * 2008-10-10 2018-12-05 PolyActiva Pty Ltd. Conjugués polymère-agent bioactif
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
HUE030895T2 (en) * 2008-10-10 2017-06-28 Polyactiva Pty Ltd Biodegradable polymer-bioactive group conjugates
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP2393828B1 (fr) 2009-02-03 2016-10-12 Amunix Operating Inc. Polypeptides recombinants étendus et compositions les comprenant
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
CN101831067A (zh) * 2010-05-31 2010-09-15 王二新 聚乙二醇脂类缀合物及其在制备药物中的应用
EP2446898A1 (fr) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Utilisation de l'hormone de croissance pour améliorer la réponse immunitaire chez des patients immunodéprimés
CN102367290B (zh) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 链官能化的多级支化聚乙二醇及其合成方法
EP3406347A3 (fr) * 2012-02-27 2019-02-13 Amunix Operating Inc. Compositions de conjugués xten et leurs procédés de fabrication
DK2947111T3 (en) * 2013-01-17 2018-05-07 Xiamen Sinopeg Biotech Co Ltd MONOFUNCTIONAL BRANCHED POLYETHYLENE LYCOL AND BIORELATED SUBSTANCE MODIFIED BY SAME
CN104877127B (zh) * 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
KR102724837B1 (ko) 2014-11-06 2024-10-31 파마에센시아 코퍼레이션 Peg화된 인터페론의 투약 요법
SG11202005952TA (en) * 2017-12-29 2020-07-29 Hoffmann La Roche Process for providing pegylated protein composition
SI3731872T1 (sl) 2017-12-29 2022-04-29 F. Hoffmann-La Roche Ag Postopek za zagotavljanje sestavka PEGiliranih beljakovin
SG11202005990RA (en) * 2017-12-29 2020-07-29 Hoffmann La Roche Process for providing pegylated protein composition

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (fr) * 1991-06-28 1993-01-07 Genentech, Inc. Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance
EP0839849A1 (fr) * 1996-11-05 1998-05-06 Nof Corporation Procédé pour la préparation d'un dérivé de polyoxyalkylène substitué par un groupe succinimidyl
WO1999003887A1 (fr) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derives d'hormone de croissance et proteines associees
JPH11228685A (ja) * 1998-02-12 1999-08-24 Nof Corp カルボキシル基含有ポリオキシアルキレン化合物
WO2000042175A1 (fr) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Techniques permettant de produire des proteines contenant des residus cysteine libres
WO2003044056A2 (fr) * 2001-11-20 2003-05-30 Pharmacia Corporation Conjugues de l'hormone de croissance humaine chimiquement modifiee
WO2004022630A2 (fr) * 2002-09-09 2004-03-18 Nektar Therapeutics Al, Corporation Alcanales polymeres solubles dans l'eau
WO2004046222A1 (fr) * 2002-11-20 2004-06-03 Nof Corporation Substance biologique modifiee, procede permettan de produire cette substance et produit intermediaire
WO2004060406A2 (fr) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Reactifs polymeres comprenant une cetone ou un groupe fonctionnel apparente
WO2005000360A2 (fr) * 2003-05-23 2005-01-06 Nektar Therapeutics Al, Corporation Derives polymeres ayant des agencements d'atomes particuliers

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (fr) * 1991-06-28 1993-01-07 Genentech, Inc. Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance
EP0839849A1 (fr) * 1996-11-05 1998-05-06 Nof Corporation Procédé pour la préparation d'un dérivé de polyoxyalkylène substitué par un groupe succinimidyl
WO1999003887A1 (fr) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derives d'hormone de croissance et proteines associees
JPH11228685A (ja) * 1998-02-12 1999-08-24 Nof Corp カルボキシル基含有ポリオキシアルキレン化合物
WO2000042175A1 (fr) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Techniques permettant de produire des proteines contenant des residus cysteine libres
WO2003044056A2 (fr) * 2001-11-20 2003-05-30 Pharmacia Corporation Conjugues de l'hormone de croissance humaine chimiquement modifiee
WO2004022630A2 (fr) * 2002-09-09 2004-03-18 Nektar Therapeutics Al, Corporation Alcanales polymeres solubles dans l'eau
WO2004046222A1 (fr) * 2002-11-20 2004-06-03 Nof Corporation Substance biologique modifiee, procede permettan de produire cette substance et produit intermediaire
WO2004060406A2 (fr) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Reactifs polymeres comprenant une cetone ou un groupe fonctionnel apparente
WO2005000360A2 (fr) * 2003-05-23 2005-01-06 Nektar Therapeutics Al, Corporation Derives polymeres ayant des agencements d'atomes particuliers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLARK R ET AL: "Long-acting growth hormones produced by conjugation with polyethylene glycol", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 271, no. 36, 6 September 1996 (1996-09-06), pages 21969 - 21977, XP002216386, ISSN: 0021-9258 *
DATABASE WPI Section Ch Week 199944, Derwent World Patents Index; Class A25, AN 1999-522765, XP002335203 *
DATABASE WPI Section Ch Week 200442, Derwent World Patents Index; Class A25, AN 2004-449738, XP002335204 *
KNAUF M J ET AL: "Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers", JOURNAL OF BIOLOGICAL CHEMISTRY 1988 UNITED STATES, vol. 263, no. 29, 1988, pages 15064 - 15070, XP002256084, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
GT200500235A (es) 2006-03-21
NO20071322L (no) 2007-05-29
TW200621291A (en) 2006-07-01
ZA200701802B (en) 2008-08-27
MX2007002441A (es) 2007-05-04
BRPI0515118A (pt) 2008-07-01
UY29088A1 (es) 2006-03-31
MA28908B1 (fr) 2007-10-01
CR8942A (es) 2007-08-16
TNSN07078A1 (fr) 2008-06-02
AP2007003919A0 (en) 2007-02-28
KR20070042567A (ko) 2007-04-23
CA2577999A1 (fr) 2006-03-09
AR050851A1 (es) 2006-11-29
JP2008511610A (ja) 2008-04-17
EP1789092A2 (fr) 2007-05-30
PE20060654A1 (es) 2006-08-12
CN101010105A (zh) 2007-08-01
NL1029828A1 (nl) 2006-03-01
WO2006024953A2 (fr) 2006-03-09
NL1029828C2 (nl) 2006-10-20
EA200700380A1 (ru) 2007-10-26
IL181085A0 (en) 2007-07-04
AU2005278903A1 (en) 2006-03-09
ECSP077281A (es) 2007-03-29

Similar Documents

Publication Publication Date Title
WO2006024953A3 (fr) Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues
WO2006014673A3 (fr) Conjugues insuline-oligomere, preparations et utilisations de ceux-ci
WO2008027854A3 (fr) Compositions pharmaceutiques à hormone de croissance humaine pour délivrance par voie orale
WO2005097202A3 (fr) Nouvelle utilisation et methode
WO2005049061A8 (fr) Formulations peptidiques a base de propylene glycol optimales pour la production et l'utilisation dans des dispositifs d'injection
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
WO2006004959A3 (fr) Peg-interferon alpha-1b
WO2003022208A3 (fr) Compositions pharmaceutiques de conjugues entre insuline medicament et oligomeres, et procedes pour traiter des affections avec ces compositions
WO2006138608A3 (fr) Compositions pharmaceutiques et leur utilisation
WO2005055945A3 (fr) Dispositifs d'administration de medicaments mucoadhesifs et procedes de fabrication et d'utilisation associes
WO2006071840A8 (fr) Formulations d'hormone de croissance humaine comportant un acide amine code de maniere non naturelle
WO2005120461A3 (fr) Formulations liposomales renfermant de la dihydrosphingomyeline, et procedes d'utilisation correspondants
EA200900451A1 (ru) Способ получения композиции эстрадиола с медленным высвобождением ( варианты ), микросферы эстрадиола и холестерина и способ для одновременной контрацепции и гормонозамещения
WO2006058539A3 (fr) Ligands du recepteur 1a de secretagogue de l'hormone de croissance
WO2005065708A3 (fr) Formulations de proteines hydrophobes dans une composition immunogenique a tolerabilite amelioree
WO2005081742A3 (fr) Formulations de dosages oraux de testostérone et procédés associés
WO2005080338A8 (fr) Nouvelles compositions pharmaceutiques a base d'esters d'acide benzilique et proteines de fusion du recepteur tnf solubles
IL180900A0 (en) Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions
WO2006050930A3 (fr) Composes a molecules conjugues presentant une activite d'absorption de cellules ameliorees
WO2004026230A3 (fr) Procedes de preparation de derives de taxanes d'acide amine et conjugues polymeres les contenant
WO2003037272A3 (fr) Conjugues de polymeres/peptides thymosine alpha 1
WO2003049699A3 (fr) Nouveaux aldehydes de polyethyleneglycol monofonctionnels
WO2005041881A8 (fr) Conjugues taxoide/acide gras et preparations les contenant
WO2007104768A3 (fr) Conjugués de protéines di-polymères et leurs procédés d'élaboration
EP1583545A4 (fr) Composition pharmaceutique pour administration améliorée de peptides dérivés de gp41 du vih et son utilisation en thérapie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 181085

Country of ref document: IL

Ref document number: 2005278903

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 553064

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005784225

Country of ref document: EP

Ref document number: 1056/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005278903

Country of ref document: AU

Date of ref document: 20050825

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 07017969

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: 2005278903

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12007500458

Country of ref document: PH

Ref document number: 2577999

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: CR2007-008942

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2007529040

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 9898

Country of ref document: GE

Ref document number: MX/a/2007/002441

Country of ref document: MX

Ref document number: 1020077004912

Country of ref document: KR

Ref document number: 200700380

Country of ref document: EA

Ref document number: 200580029117.1

Country of ref document: CN

Ref document number: DZP2007000150

Country of ref document: DZ

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005784225

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0515118

Country of ref document: BR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载